ArticleDrug safety - case reports2019
Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report.
Article in Drug safety - case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05742295 (Preventing Cefoperazone/Sulbactam Induced Coagulopathy in Critically Ill Egyptian Patients), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preventing Cefoperazone/Sulbactam Induced Coagulopathy in Critically Ill Egyptian Patients: Efficacy of Vitamin K Prophylactic Doses
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2019Pooled it
- Extreme and rapidly reversible prolongation of prothrombin time during cefoperazone/sulbactam therapy in a patient with gastrointestinal dysfunction and parenteral nutrition: a case report.Frontiers in pharmacology · 2026Article
- Severe delayed coagulopathy caused by cefoperazone/sulbactam: A case report.The Journal of international medical research · 2025Article
- Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses.Hospital pharmacy · 2024Article
- Development and internal validation of a model for predicting cefoperazone/sulbactam-associated coagulation disorders in Chinese inpatients.BMC pharmacology & toxicology · 2024Article
- The clinical features and risk factors of coagulopathy associated with cefoperazone/sulbactam: a nomogram prediction model.Frontiers in pharmacology · 2024Article
- Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.Pharmacology · 2023Article
- Article
- Neglected vitamin K deficiency causing coagulation dysfunction in an older patient with pneumonia: a case report.BMC geriatrics · 2022Article
- Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report.Infectious agents and cancer · 2022Article
- Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.Antibiotics (Basel, Switzerland) · 2022Article
- Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database.Thrombosis journal · 2022Article
- Signal Detection of Pediatric Drug-Induced Coagulopathy Using Routine Electronic Health Records.Frontiers in pharmacology · 2022Article
- Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.Infection and drug resistance · 2021Article
- Article
- Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.European journal of clinical pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a suspected and fatal adverse reaction involving vitamin K-dependent coagulopathy that might be associated with cefoperazone/sulbactam (CPZ/SAM), a combined antimicrobial formulation. We reported a patient diagnosed with acute cerebral infarction and secondary pulmonary infection who was treated with an intravenous infusion of CPZ/SAM at 3 g twice daily. After receiving treatment with CPZ/SAM, the patient developed a fatal adverse reaction of CPZ-induced hemorrhage. The Naranjo assessment score in this report was 5, suggesting that the patient's coagulation function disorder was potentially associated with the use of CPZ/SAM. To prevent vitamin K-dependent coagulopathy caused by CPZ/SAM, it is suggested to avoid cephalosporins in patients with a high risk of bleeding unless the need for cephalosporins is compelling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.